Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

Guides · Weight loss · pricing

Weight Loss Peptides Philippines 2026

Three GLP-1-class compounds lead the weight-loss conversation in the Philippines. This filing sets out what their phase 3 trials reported, with side effects alongside, where each one stands with regulators, and where the prices live: registered pharmacy pens on one side, research-grade vials on the other.

Philippines Peptides editorial deskUpdated 10 min read

Short answer

As of 23 September 2026, three GLP-1-class compounds lead: semaglutide and tirzepatide, registered here as prescription medicines, and retatrutide, still investigational. Top-arm weight loss in their main trials: 14.9% at 68 weeks in STEP 1, 20.9% at 72 weeks in SURMOUNT-1 and 28.3% at 80 weeks in TRIUMPH-1, all phase 3.

Video guide: GLP-1 Prices in the Philippines, Checked September 2026 (2:10)
Video transcript

Searched for the GLP-1 price in the Philippines? Here is every branded pen price on our tracker, checked 23 September 2026. The tracker holds 55 prices from 7 pharmacies and clinics, each read from the seller's own product page. Ozempic runs from ₱7,599 to ₱9,280 per pen. Wegovy, from ₱9,890 to ₱14,761. Mounjaro has the widest spread: ₱11,650 for the lowest strength, up to ₱30,000 for the highest. Saxenda lists at about ₱3,380. Rybelsus is registered with FDA Philippines, but no chain lists a price online, and Mercury Drug publishes no prices at all. Every one of these is a prescription medicine in the Philippines. Prescribing belongs with a licensed Philippine physician. The same molecules are also sold a second way: as research vials, from our partner and supplier, Primara Labs. These are not the same product. The pen is a registered prescription medicine. A research vial is not approved for human use and is sold for research only. Primara's 15 mg vials: semaglutide, ₱1,990. Tirzepatide, ₱1,890. And retatrutide, with no pharmacy pen at all, [₱3,390 for the 20 mg vial]. Per mg, the Ozempic pen is about ₱2,320. The semaglutide research vial works out at ₱133 per mg, or ₱81 in a 10 pack. Mounjaro is about ₱498 per mg. The tirzepatide research vial works out at ₱126 per mg. Not the same product. Every vial order includes bacteriostatic water, syringes and alcohol pads. Same day in Metro Manila before noon, J&T to the provinces, and a 60-day money-back guarantee. Read the full price tracker on Philippines Peptides, then see the research vials at Primara Labs and order on WhatsApp. [Figures in square brackets corrected on 3 November 2026 from Primara's current catalogue: the narration gives the price of the 15 mg retatrutide vial, retired on 12 October 2026.]

Snapshot

RETATRUTIDE (TRIUMPH-1)
28.3% / 80 wks
TIRZEPATIDE (SURMOUNT-1)
20.9% / 72 wks
SEMAGLUTIDE (STEP 1)
14.9% / 68 wks
RETATRUTIDE STATUS
Investigational

Retatrutide has no registered form anywhere. Primara Labs, our partner and supplier, lists retatrutide 20mg at ₱3,775 a vial, or ₱3,390 with the standing 10% off, dispatched same day for Metro Manila orders placed before 12 noon. Retatrutide at Primara Labs

Three molecules dominate the weight-loss peptide conversation in the Philippines: retatrutide, tirzepatide and semaglutide. Semaglutide and tirzepatide are registered here as prescription medicines; retatrutide is investigational and approved nowhere. Every trial figure on this page is read from the synced trial dataset, not typed.

Phase 3 Trial Results

CompoundTrialBody weight, top armAdverse events, same trialStatus
RetatrutideTRIUMPH-1, phase 3, 80 weeks, n=2,339-28.3% on 12 mg (placebo -2.2%)Nausea: 28.6%, 38.4% and 42.4% on the 4, 9 and 12 mg arms, against 14.8% on placebo; Discontinuation for adverse events: 4.1%, 6.9% and 11.3% on the 4, 9 and 12 mg arms, against 4.9% on placebo.Investigational; no US or EU approval
TirzepatideSURMOUNT-1, phase 3, 72 weeks, n=2,539-20.9% on 15 mg (placebo -3.1%)Discontinuation for adverse events: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg arms, against 2.6% on placebo.Registered in PH as Mounjaro (prescription)
SemaglutideSTEP 1, phase 3, 68 weeks, n=1,961-14.9% on 2.4 mg (placebo -2.4%)Not in the synced dataset for STEP 1; see the semaglutide guideRegistered in PH as Ozempic, Wegovy and Rybelsus (prescription)

In TRIUMPH-1, a 80-week phase 3 trial of 2,339 adults with obesity or overweight without diabetes, body weight fell 28.3% on the 12 mg retatrutide arm, against 2.2% on placebo. TRIUMPH-1 adverse events: Nausea: 28.6%, 38.4% and 42.4% on the 4, 9 and 12 mg arms, against 14.8% on placebo; Discontinuation for adverse events: 4.1%, 6.9% and 11.3% on the 4, 9 and 12 mg arms, against 4.9% on placebo.

In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with obesity or overweight without diabetes, body weight fell 20.9% on the 15 mg tirzepatide arm, against 3.1% on placebo. SURMOUNT-1 adverse events: Discontinuation for adverse events: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg arms, against 2.6% on placebo.

In STEP 1, a 68-week phase 3 trial of 1,961 adults with obesity or overweight without diabetes, body weight fell 14.9% on the 2.4 mg semaglutide arm, against 2.4% on placebo.

Two caveats before anyone treats this table as a leaderboard. First, these are separate trials with different durations and populations, not one head-to-head. The head-to-head that does exist compared tirzepatide with semaglutide: In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity and no type 2 diabetes that compared the two directly, body weight fell 20.2% on tirzepatide against 13.7% on semaglutide, each at the maximum tolerated dose. Second, each figure is the highest-dose arm of its trial, and a trial average is not a personal forecast.

Retatrutide also has an earlier phase 2 result: in a 48-week phase 2 trial of 338 adults with obesity or overweight, body weight fell 24.2% on the 12 mg arm, against 2.1% on placebo. The phase 3 figure above is the more mature one.

Prices

Semaglutide and tirzepatide are also sold as registered prescription medicines, and those pens have published pharmacy prices. They are medicines dispensed against a prescription and are not interchangeable with a research vial, so this page does not set the two side by side. The dated pen prices are on the Ozempic price page, the Wegovy price page, the Mounjaro price page and the GLP-1 price tracker.

Retatrutide has no registered form anywhere. Primara Labs, our partner and supplier, lists retatrutide 20mg at ₱3,775 a vial, or ₱3,390 with the standing 10% off. Research-grade vial prices for other compounds are in the peptide price index.

Compound Notes

Semaglutide is a GLP-1 receptor agonist. In the Philippines it is registered as Ozempic, Wegovy and Rybelsus, all prescription medicines. The semaglutide guide covers its trials and side effects.

Tirzepatide adds GIP receptor agonism to GLP-1. In the Philippines it is registered as Mounjaro, a prescription medicine. The tirzepatide guide covers its trials and side effects.

Retatrutide is the triple agonist, acting on GLP-1, GIP and glucagon receptors. It has no registered form anywhere. Next milestone, per the Eli Lilly press release dated 23 July 2026: Sponsor plans a US Biologics License Application submission in Q1 2027. The retatrutide Philippines guide and the TRIUMPH results guide cover it in depth.

Finished reading and not sure where a 90-day plan would start? Longevity Manila builds one around a single goal, then hands the list to our partner and supplier, Primara Labs.

The Next Wave

Two more names come up in reader questions. Cagrilintide is an amylin analogue studied in combination with semaglutide, and mazdutide is a dual GLP-1 and glucagon receptor agonist. What their trials measured is on each compound page.

Sourcing and the Law

The registered route runs through a prescription and a registered pharmacy counter, and prescribing belongs with a licensed Philippine physician. Under RA 9711 a drug must be registered with FDA Philippines before it is imported, sold or distributed; what that means for each compound is in the regulatory status page.

A research-grade vial is not a registered medicine and not a substitute for a prescribed pen. Read the GLP-1 side effects guide and the legality guide before deciding anything, not after.

FAQ

How much do weight loss peptides cost in the Philippines?

Primara Labs, our partner and supplier, lists retatrutide 20mg at ₱3,775 a vial, or ₱3,390 with the standing 10% off. Semaglutide and tirzepatide are also sold as registered prescription pens, a separate market with its own published pharmacy prices, covered on the Ozempic, Wegovy and Mounjaro price pages. A research-grade vial is not a registered medicine and not a substitute for a prescribed pen.

What is the strongest weight loss peptide?

By published phase 3 data, retatrutide. In TRIUMPH-1, a 80-week phase 3 trial of 2,339 adults with obesity or overweight without diabetes, body weight fell 28.3% on the 12 mg retatrutide arm, against 2.2% on placebo. TRIUMPH-1 adverse events: Nausea: 28.6%, 38.4% and 42.4% on the 4, 9 and 12 mg arms, against 14.8% on placebo; Discontinuation for adverse events: 4.1%, 6.9% and 11.3% on the 4, 9 and 12 mg arms, against 4.9% on placebo. Its earlier phase 2 trial reported 24.2% on the 12 mg arm at 48 weeks. In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with obesity or overweight without diabetes, body weight fell 20.9% on the 15 mg tirzepatide arm, against 3.1% on placebo. SURMOUNT-1 adverse events: Discontinuation for adverse events: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg arms, against 2.6% on placebo. In STEP 1, a 68-week phase 3 trial of 1,961 adults with obesity or overweight without diabetes, body weight fell 14.9% on the 2.4 mg semaglutide arm, against 2.4% on placebo. Retatrutide is investigational and approved nowhere.

Is tirzepatide or semaglutide better for weight loss?

In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity and no type 2 diabetes that compared the two directly, body weight fell 20.2% on tirzepatide against 13.7% on semaglutide, each at the maximum tolerated dose. That is a trial average, not a forecast for any individual. Both are registered in the Philippines as prescription medicines, and prescribing belongs with a licensed Philippine physician.

Are weight loss peptides legal in the Philippines?

Under RA 9711 a drug must be registered with FDA Philippines before it is imported, sold or distributed. Semaglutide (Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro) are registered as prescription medicines. Research-grade vials of these or other compounds are not registered medicines. The regulation hub on this site covers the detail.

Where do people in the Philippines buy weight loss peptides?

Registered pens come from pharmacy counters with a prescription from a licensed Philippine physician; Watsons, Southstar Drug and Rose Pharmacy publish their pen prices online, and Mercury Drug does not. Research-grade vials are sold by suppliers such as Primara Labs, our partner and supplier, which dispatches same day for Metro Manila orders placed before 12 noon, and in 1 to 5 business days elsewhere in the country. A research-grade vial is not a substitute for a prescribed pen.

Updated